The US Food and Drug Administration has approved Celltrion's biosimilar of Johnson & Johnson's Remicade (infliximab) - but the launch date of the blockbuster's cheaper rival remains uncertain.

Johnson & Johnson has come out fighting after Pfizer announced yesterday that it is ready to launch a biosimilar competitor to its blockbuster Remicade. J&J said it had a “biosimilar ...

Birmingham, UK - Although infliximab (Remicade, Centocor) was licensed for use in the treatment of ankylosing spondylitis (AS) in Europe nearly 2 years ago, in the UK there has been little ...